XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED CONSOLIDATED STATEMENT OF INCOME - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Income Statement [Abstract]        
Sales $ 14,593 $ 11,402 $ 30,494 $ 22,029
Costs, Expenses and Other        
Cost of sales 4,216 3,104 9,596 6,303
Selling, general and administrative 2,512 2,281 4,834 4,468
Research and development 2,798 4,321 5,374 6,732
Restructuring costs 142 82 194 380
Other (income) expense, net 438 (103) 1,148 (558)
Total Costs, Expenses and Other 10,106 9,685 21,146 17,325
Income from Continuing Operations Before Taxes 4,487 1,717 9,348 4,704
Taxes on Income from Continuing Operations 538 503 1,092 741
Net Income from Continuing Operations 3,949 1,214 8,256 3,963
Less: Net Income Attributable to Noncontrolling Interests 5 1 2 5
Net Income from Continuing Operations Attributable to Merck & Co., Inc. 3,944 1,213 8,254 3,958
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 0 332 0 766
Net Income Attributable to Merck & Co., Inc. $ 3,944 $ 1,545 $ 8,254 $ 4,724
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:        
Income from Continuing Operations (in dollars per share) $ 1.56 $ 0.48 $ 3.26 $ 1.56
Income from Discontinued Operations (in dollars per share) 0 0.13 0 0.30
Net Income (in dollars per share) 1.56 0.61 3.26 1.87
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:        
Income from Continuing Operations (in dollars per share) 1.55 0.48 3.25 1.56
Income from Discontinued Operations (in dollars per share) 0 0.13 0 0.30
Net Income (in dollars per share) $ 1.55 $ 0.61 $ 3.25 $ 1.86